Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.

In March, Viridian posted a phase 3 win for elegrobart in active TED, defined as patients who developed symptoms within 15 ...

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by ...

-- TEPEZZA significantly improved the clinical course of Thyroid Eye Disease (TED) in all patient subgroups, including those with more severe disease at baseline -- -- For patients in the follow-up ...

Because it's rare and not always top of mind for doctors, TED can quietly progress or be mistaken for allergies or Graves' ...

Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease May 5, 2026 8:00 ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Patients who received Tepezza to treat thyroid eye disease showed improved extraocular muscle size ...

Amgen announced positive topline results from a phase 3 trial of Tepezza (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with ...

-- New findings presented during the Academy of Managed Care Pharmacy Nexus 2020 Virtual Meeting showed most patients had at least some improvement in one or more disease parameters for up to one year ...

THOUSAND OAKS, Calif., Sept. 24, 2024 /PRNewswire/ -- Amgen (AMGN) today announced TEPEZZA ® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high ...

Living with a rare disease can often mean days upon months upon years of searching for answers. Unfortunately, this is the case for many who are living with Thyroid Eye Disease (TED) – a rare ...